Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11935000 | 0.85 | SELP (0.49) | — | |
| SCHEMBL12028671 | 0.84 | SLC7A5 (0.46) | SLC7A5TLR7MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL17090493 | 0.81 | TLR7 (0.40) | SLC7A5TLR7MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL17090495 | 0.81 | GRIA1 (0.43) | SLC7A5TLR7MTNR1AMTNR1BSYK | |
| SCHEMBL12028667 | 0.81 | SLC7A5 (0.48) | SLC7A5TLR7MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL11934998 | 0.80 | MTNR1A (0.52) | TLR7MTNR1AMTNR1BALDH1A1SMN1; SMN2 | |
| SCHEMBL18530377 | 0.79 | SLC7A5 (0.56) | SLC7A5TLR7MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL4979499 | 0.79 | SLC7A5 (0.51) | SLC7A5TLR7ALDH1A1GAAGFER | |
| SCHEMBL13113859 | 0.79 | MAPT (0.44) | SYKSMN1; SMN2GHSRHTT | |
| SCHEMBL17869670 | 0.77 | SLC7A5 (0.56) | SLC7A5TLR7ALDH1A1GAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-8227618-B2 | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof | SHIONOGI & CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20100273841-A1 | AMINE-DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | NPY5R, NPY1R, NPY2R | SLC7A5 230/4885TLR7 404/4885MTNR1A 170/4885 |
| US-20100273841-A1 | AMINE-DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | NPY5R, NPY1R, NPY2R | SLC7A5 248/4885TLR7 416/4885MTNR1A 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.